UBS Group
KRRO icon

UBS Group’s Korro Bio KRRO Stock Holding History

UBS Group’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Buy
105,453
+83,777
+386% +$1.04M ﹤0.01% 5437
2026
Q1 		$245K Buy
21,676
+1,681
+8% +$18.5K ﹤0.01% 6520
2025
Q4 		$160K Sell
19,995
-33,108
-62% -$774K ﹤0.01% 6679
2025
Q3 		$2.54M Buy
53,103
+34,522
+186% +$766K ﹤0.01% 4731
2025
Q2 		$232K Sell
18,581
-55,630
-75% -$801K ﹤0.01% 6623
2025
Q1 		$1.29M Buy
74,211
+1,172
+2% +$34.8K ﹤0.01% 5059
2024
Q4 		$2.78M Buy
73,039
+63,309
+651% +$3.25M ﹤0.01% 4403
2024
Q3 		$325K Buy
9,730
+5,317
+120% +$224K ﹤0.01% 5520
2024
Q2 		$149K Buy
4,413
+4,142
+1,528% +$229K ﹤0.01% 5869
2024
Q1 		$24.4K Sell
271
-366
-57% -$20K ﹤0.01% 6830
2023
Q4 		$30.5K Buy
637
+600
+1,622% +$19.8K ﹤0.01% 6836
2023
Q3 		$693 Sell
37
-49
-57% -$1.23K ﹤0.01% 8330
2023
Q2 		$1.49K Sell
86
-25
-23% -$485 ﹤0.01% 7908
2023
Q1 		$2.79K Sell
111
-42
-27% -$4.79K ﹤0.01% 8442
2022
Q4 		$29.4K Buy
153
+27
+21% +$2.78K ﹤0.01% 7256
2022
Q3 		$11K Sell
126
-5
-4% -$508 ﹤0.01% 8303
2022
Q2 		$10K Hold
131
– – ﹤0.01% 7968
2022
Q1 		$14K Sell
131
-150
-53% -$28.7K ﹤0.01% 7948
2021
Q4 		$72K Buy
281
+263
+1,461% +$79.9K ﹤0.01% 6592
2021
Q3 		$7K Sell
18
-18
-50% -$7.08K ﹤0.01% 8316
2021
Q2 		$18K Sell
36
-585
-94% -$286K ﹤0.01% 7449
2021
Q1 		$296K Buy
621
+586
+1,674% +$1.14M ﹤0.01% 5210
2020
Q4 		$62K Buy
35
+19
+119% +$25.1K ﹤0.01% 6000
2020
Q3 		$15K Sell
16
-178
-92% -$191K ﹤0.01% 6521
2020
Q2 		$226K Buy
194
+111
+134% +$100K ﹤0.01% 4723
2020
Q1 		$74K Sell
83
-78
-48% -$84.2K ﹤0.01% 5526
2019
Q4 		$141K Buy
+161
New +$125K ﹤0.01% 5821

Other funds holding KRRO

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

UBS Group's KRRO Position: Q2 2026 in Review

UBS Group increased its Korro Bio (KRRO) stake by 386% in Q2 2026, buying an estimated $1.04M and bringing the position to 105,453 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #5437.

UBS Group first reported a position in KRRO in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.78M in Q4 2024. 106 funds tracked by Wall St. Rank hold KRRO as of Q2 2026.

  • UBS Group held 105,453 shares of Korro Bio worth $1.39M as of Q2 2026.
  • UBS Group bought 83,777 Korro Bio shares in Q2 2026, an estimated $1.04M.
  • Korro Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5437 holding.
  • UBS Group first reported a position in Korro Bio in Q4 2019 and has held it in 27 quarters since.
  • UBS Group's Korro Bio position peaked at $2.78M in Q4 2024.
  • 106 funds tracked by Wall St. Rank held Korro Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.